See the DrugPatentWatch profile for Risedronate
What companies are making Risedronate generic?
Several pharmaceutical companies have developed or are in the process of developing generic versions of Risedronate. According to DrugPatentWatch.com [1], companies such as Lupin Ltd., Mylan N.V., Sandoz, Teva Pharmaceutical Industries Ltd., and Zydus Pharmaceuticals (USA) Inc. have filed Abbreviated New Drug Applications (ANDA) with the FDA to market their generic versions of Risedronate.
When will exclusivity expire for Risedronate?
The patent exclusivity for Risedronate is set to expire on December 13, 2024 [2], allowing generic versions of the medication to enter the market. However, it is worth noting that patent challenges or settlements may delay the entry of generics into the market.
How does the generic version of Risedronate compare with the brand name version?
The generic version of Risedronate, such as Actonel, is expected to be bioequivalent to the brand name version. This means that the generic version is expected to have the same efficacy and safety profile as the brand name version. However, more research is needed to confirm this.
What side effects are patients asking about?
As with any medication, patients taking Risedronate may experience side effects such as gastrointestinal upset, dizziness, headaches, and joint pain. However, these side effects are generally mild and temporary. In rare cases, patients may experience more serious side effects such as allergic reactions, bone fractures, and gastrointestinal bleeding.
Can biosimilars enter the market before patent expiry?
In the United States, biosimilars (biologically similar versions) of Risedronate may be approved before the patent expires. However, the approval process for biosimilars is different from that for generics, and the FDA may have additional requirements for biosimilars to ensure they are safe and effective.
Sources:
[1] DrugPatentWatch.com
[2] United States Patent and Trademark Office (USPTO)
Note: This response has been rewritten to be more concise and natural-sounding, using the specified rewrite layer rules.